SEONGNAM-SI, South Korea, January 22, 2025 – L&C Bio, led by CEO Hwan-Chul Lee, has made headlines by becoming the first company to get approval in China for its acellular dermal matrix, called “MegaDerm Plus.” This achievement could help the company tap into China’s growing regenerative medicine market, with sales expected to kick off in the first half of 2025.
Recently, China has struggled with a shortage of human tissue products, partly due to issues with illegal donor practices. This has caused major disruptions to local businesses. In this challenging landscape, “MegaDerm Plus” stands out as a crucial solution that could help fill that gap.
Interest in “MegaDerm Plus” is buzzing among leading medical device companies, hospitals, and healthcare professionals in China. This growing enthusiasm indicates that L&C Bio is well-positioned not just to enter the market but to make a lasting impact in the field of regenerative medicine.
L&C Bio has also announced plans to fully acquire its subsidiary, L&C China, using internal funds. This strategy is notable because it allows them to avoid issuing new bonds, keeping the company’s debt levels low and its management stable.
- Financial Stability: By using internal resources for the acquisition, L&C Bio minimizes debt, leading to stronger financial management.
- Secured Management Control: Full ownership enables the company to make independent decisions about contracts and strategies in China.
- Faster Decision-Making: Complete control allows for quick responses to market needs and opportunities.
This strategic move is seen as a key step for L&C Bio’s long-term growth in China. By avoiding debt complications, CEO Hwan-Chul Lee is positioning the company for success without the risks tied to management disputes or stock dilution.
If a major medical device company were to invest in L&C China, the resulting funds would go directly to L&C Bio, potentially leading to substantial profits by the end of 2025. Not only does this open doors for growth, but it also enhances L&C Bio’s corporate value, allowing for better access to medical networks and distribution channels in China.
L&C Bio has experienced rapid growth since its founding in 2011. It went public on KOSDAQ in 2018 and reached a market cap of over KRW 1 trillion by 2020. With the new NMPA approval, the company is poised for further expansion.
According to CEO Hwan-Chul Lee, “This approval marks a pivotal moment for us. It’s a stepping stone towards our goal of being a global leader in regenerative medicine based on human tissue.” The road ahead looks promising for L&C Bio, with innovative technologies and a strong commitment to growth shaping its future in the international market.
For more information, you can view the original announcement here.
Check out this related article: Why President Trump Should Reconsider Leaving the World Health Organization: Insights from Gordon Brown
Source linkChina, regenerative medicine, NMPA, human tissue, National Medical Products Administration, global market, MegaDerm
